Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence ( AI ) Stock
Recursion is about to go toe-to-toe with the largest healthcare company.
This Unstoppable Growth Stock Just Gave Investors More Reasons to Buy
The stock didn't stay down for too long.
RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals narrows its Q3 loss but posts lower-than-expected revenues due to reduced collaboration revenues from its partners.
Recursion Pharmaceuticals ( RXRX ) Reports Q3 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +5.26% and -70.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 Things Investors Need to Know About Recursion Pharmaceuticals
Can this under-the-radar stock be a great way to cash in on AI?
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
RXRX gears up for Q3 results as it refocuses its pipeline and collaboration-driven revenue strategy.
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence ( AI ) Stock?
Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.
Earnings Preview: Recursion Pharmaceuticals ( RXRX ) Q3 Earnings Expected to Decline
Recursion Pharmaceuticals (RXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion Pharmaceuticals ( RXRX ) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $5.91, indicating a -6.19% shift from the previous trading day.
AI in Biotechnology Market to Reach $11.4 Billion by 2030
Boston, Oct. 24, 2025 ( GLOBE NEWSWIRE ) -- Artificial intelligence ( AI ) is transforming biotechnology, from accelerating drug discovery and streamlining clinical trials to enhancing diagnostics and genomic research.
Recursion Pharmaceuticals ( RXRX ) Dips More Than Broader Market: What You Should Know
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.75, marking a -5.89% move from the previous day.
Up 25% in 1 Month, Is This Stock a Buy?
It might look like this beaten-down AI-focused company is finally bouncing back, but don't be too quick to pull the trigger.
Recursion Pharmaceuticals ( RXRX ) CEO Sells 100,000 Shares
Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals ( NASDAQ:RXRX ) , reported the sale of 100,000 shares on October 10, 2025, as disclosed in a SEC Form 4 filing. It appears that Gibson converted 120,000 shares of class B common stock to class A common stock.
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday - American Battery Tech ( NASDAQ:ABAT ) , Amazon.com ( NASDAQ:AMZN )
U.S. stocks were higher, with the Nasdaq Composite gaining more than 1% on Monday. Shares of WW International, Inc. ( NASDAQ:WW ) rose sharply during Monday's session after announcing a partnership with Amazon.com, Inc.'s ( NASDAQ:AMZN ) Amazon Pharmacy to make weight management medications ...
3 Growth Stocks to Invest $1,000 in Right Now
Not every promising prospect is currently priced too richly relative to its risk.
Recursion Pharmaceuticals ( RXRX ) Suffers a Larger Drop Than the General Market: Key Insights
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $6.36, moving 6.33% from the previous trading session.
Is Recursion Pharmaceuticals a Millionaire Maker?
This is the only biotech stock to attract an investment from artificial intelligence (AI) giant Nvidia.
Morgan Stanley, T1 Energy, Bunge Global, Bank of America And Other Big Stocks Moving Higher On Wednesday - Bank of America ( NYSE:BAC ) , Applied Digital ( NASDAQ:APLD )
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. Shares of Morgan Stanley ( NYSE:MS ) rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results.
4 Healthcare Stocks to Buy Now
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.
COST, AMD, RXRX, CIFR, SNOW: 5 Trending Stocks Today - Advanced Micro Devices ( NASDAQ:AMD )
On Wednesday, major U.S. indices closed mixed, with the Nasdaq rising 1.1% to 23,043.38 and the S&P 500 slipping nearly 0.6% to 6,753.72. The Dow Jones Industrial Average was unchanged at 46,601.78. These are the top stocks that gained the attention of retail traders and investors through the day:
What's Going On With Recursion Pharmaceuticals Stock On Wednesday? - Recursion Pharmaceuticals ( NASDAQ:RXRX )
Recursion Pharmaceuticals Inc. ( NASDAQ:RXRX ) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, as per data from Benzinga Pro.
Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday - Century Aluminum ( NASDAQ:CENX ) , Absci ( NASDAQ:ABSI )
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Wednesday. Shares of Dell Technologies Inc. ( NYSE:DELL ) shares rose sharply during Wednesday's session.
Recursion Pharmaceuticals ( RXRX ) Dips More Than Broader Market: What You Should Know
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $5.23, representing a -5.42% change from its previous close.
Recursion Pharmaceuticals ( RXRX ) Surges 8.2%: Is This an Indication of Further Gains?
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nvidia Has Invested in These 6 Companies. Should You Follow Suit?
The world's most valuable company holds stakes in a number of smaller tech players.
Where Will Recursion Pharmaceuticals Be in 5 Years?
Could investing in this stock be an underrated way to profit from the rapidly expanding AI industry?
The Biotech Stock That's Too Risky for Most Investors
It's unclear how long it's going to be before this company has a product to sell.
10 Hidden-Gem AI Stocks to Buy Right Now
From AI-powered insurance bots to drug discovery platforms, these overlooked stocks offer pure-play exposure to artificial intelligence without trillion-dollar valuations.
Jim Cramer Says This Financial Stock Is A 'Total Spec,' Likes Dutch Bros, - Dutch Bros ( NYSE:BROS ) , American Bitcoin ( NASDAQ:ABTC )
On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Dutch Bros ( NYSE: BROS ) . He recommended buying some now and then buying some of the stock in the $40s. On Sept. 24, RBC Capital analyst Logan Reich reiterated Dutch Bros with an Outperform and maintained a price target of $85.
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now
BigBear.ai is bigger than both of these AI-focused companies now. That could change.
Recursion Pharmaceuticals ( RXRX ) Laps the Stock Market: Here's Why
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.98, representing a +1.32% change from its previous close.
Recursion Pharmaceuticals ( RXRX ) Stock Sinks As Market Gains: What You Should Know
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $4.77, signifying a -1.24% move from its prior day's close.
Nvidia Has $4.3 Billion Invested in These 6 Artificial Intelligence ( AI ) Stocks. Here's the Best of the Bunch.
Most of Nvidia's AI bets are riding on one stock.
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patient Enrolled - Biodexa Pharmaceuticals ( NASDAQ:BDRX ) , Pfizer ( NYSE:PFE )
Reports Being On Track To Be First Mover In $7B Market With No Current Therapeutic Options
3 AI Stocks Disrupting Trillion-Dollar Industries
These three companies are using artificial intelligence (AI) to transform defense, pharmaceuticals, and banking.
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
This AI company isn't yet living up to the hype.
1 Monster Nvidia-Backed Artificial Intelligence ( AI ) Data Center Stock To Buy Hand Over Fist Before It Soars 20%, According to a Wall Street Analyst
Filings indicate that Nvidia holds an equity stake in a leading data center operation.
1 Reason to Buy This Beaten-Down Artificial Intelligence ( AI ) Stock, and 2 Reasons to Sell
There might be better artificial intelligence (AI) stocks out there to buy.
The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode
The artificial intelligence revolution is leaving no opportunity unaddressed.
Why Recursion Pharmaceuticals Stock Caught a Cold This Week
The few news items from and about the company weren't all that positive.
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
These companies are in the right place at the right time with the right products.
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.
Why Recursion Pharmaceuticals Stock Tanked on Tuesday
It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.
Recursion ( RXRX ) Q2 Revenue Jumps 33%
Recursion Pharmaceuticals ( NASDAQ:RXRX ) , a technology-driven biotech company decoding biology using artificial intelligence for drug discovery, released its financial results for the second quarter of 2025 on August 5, 2025.
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates - Recursion Pharmaceuticals ( NASDAQ:RXRX )
Recursion reports second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million. Recursion reports a second-quarter loss of 41 cents per share, missing estimates for a loss of 34 cents per share. The market's back, and these 3 income stocks are thriving. See them here→
Recursion Pharmaceuticals ( RXRX ) Reports Q2 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -17.14% and +33.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
2 Beaten-Down Stocks With Incredible Upside Potential
Getting in on the ground floor with these companies might lead to superior returns.
Gilead Sciences ( GILD ) Expected to Beat Earnings Estimates: Should You Buy?
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion Pharmaceuticals ( RXRX ) Registers a Bigger Fall Than the Market: Important Facts to Note
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $5.81, moving 2.35% from the previous trading session.
